NIMH SYNTHESIS AND DISTRIBUTION OF DRUGS OF ABUSE AND RELATED COMPOUNDS. JUNE 16, 2023 - JUNE 15, 2024. TASK ORDER 75N95023F00002 (TO5). N01DA-22-8944.

NIMH 滥用药物及相关化合物的合成和分销。

• 批准号: 10933157
• 负责人: KATIE HAYES
• 金额: $ 42.18万
• 依托单位: RESEARCH TRIANGLE INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-06-16 至 2024-06-15
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10933157
• 关键词: Agonist; Area; Basic Science; Behavioral; Biochemical; Brain imaging; Central Nervous System; Clinical Research; Clinical Trials; Functional Magnetic Resonance Imaging; Good Manufacturing Process; Human; Legal patent; Ligands; Longitudinal Studies; Mental Health; Molecular; National Institute of Mental Health; Pharmaceutical Preparations; Pharmacology; Positron-Emission Tomography; Primates; Psychotropic Drugs; Radiolabeled; Signal Transduction; Source; antagonist; chemical synthesis; drug distribution; drug of abuse; novel; programs; receptor; single photon emission computed tomography

The purpose of the NIMH Chemical Synthesis and Drug Supply Program is to synthesize, purify, and provide essential compounds that are unavailable from commercial sources (e.g., the stock has been depleted and it will not be replenished, patented compounds that are unavailable while undergoing clinical trials, etc.) to stimulate basic and clinical research relevant to mental health in areas such as the molecular pharmacology and signaling of CNS receptors, longitudinal studies to evaluate the molecular, biochemical, and behavioral actions of psychoactive compounds, and functional brain imaging in primates and humans. The present initiative focuses on the synthesis of current GMP (Good Manufacturing Practices) and non-GMP compounds for basic and clinical research such as novel central nervous system receptor subtype-selective agonists and antagonists, radiolabeled compounds, and novel PET, SPECT, and fMRI ligands for functional brain imaging.

NIMH化学合成和药物供应计划的目的是合成，纯化和提供基本的化合物，这些化合物无法从商业来源中获得（例如，股票已经耗尽，将不补充，并不补充专利的化合物，这些化合物是不可避免的，这些化合物是不可避免的，这些化合物在接受临床和临床研究方面是不可避免的，例如，在经过临床方面的临床研究，以促进临床研究，以促进精神健康的健康。受体，纵向研究，以评估精神活性化合物的分子，生化和行为作用以及灵长类动物和人类的功能性脑成像。本计划的重点是用于基本和临床研究的当前GMP（良好的制造实践）和非GMP化合物，例如新型中心神经系统受体受体亚型亚型选择性激动剂和拮抗剂，放射性标记化合物，新型PET，SPECT，SPECT和FIMRI，用于功能性大脑的磁磁性。